Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CG Oncology (CGON) Other financing activities (2023 - 2025)

CG Oncology's Other financing activities history spans 3 years, with the latest figure at $593000.0 for Q4 2025.

  • For Q4 2025, Other financing activities fell 91.34% year-over-year to $593000.0; the TTM value through Dec 2025 reached $316000.0, down 90.77%, while the annual FY2025 figure was $316000.0, 90.77% down from the prior year.
  • Other financing activities reached $593000.0 in Q4 2025 per CGON's latest filing, up from $270000.0 in the prior quarter.
  • In the past five years, Other financing activities ranged from a high of $6.8 million in Q4 2024 to a low of -$3.4 million in Q1 2024.
  • Average Other financing activities over 3 years is $928875.0, with a median of $116500.0 recorded in 2024.
  • The largest YoY upside for Other financing activities was 93.15% in 2025 against a maximum downside of 751.35% in 2025.
  • A 3-year view of Other financing activities shows it stood at $3.7 million in 2023, then skyrocketed by 85.53% to $6.8 million in 2024, then plummeted by 91.34% to $593000.0 in 2025.
  • Per Business Quant, the three most recent readings for CGON's Other financing activities are $593000.0 (Q4 2025), $270000.0 (Q3 2025), and -$315000.0 (Q2 2025).